SEARCH

SEARCH BY CITATION

References

  • 1
    National Institute for Clinical Excellence. Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. London: NICE, 2002.
  • 2
    Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005;2:e141.
  • 3
    Mangalore R, Knapp M. Cost of schizophrenia in England. J Ment Health Policy Econ 2007;10:2341.
  • 4
    National Institute for Health and Clinical Excellence (NICE). Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. London: NICE, 2003.
  • 5
    Bagnall AM, Jones L, Ginnelly L, et al. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess 2003;7:1193.
  • 6
    Ginnelly L, Manca A. The use of decision models in mental health economic evaluation: challenges and opportunities. Appl Health Econ Health Policy 2003;2:15764.
  • 7
    Hunink M, Glasziou P. Decision Making in Health and Medicine; Integrating Evidence and Values (3rd ed.). Cambridge: The Press Syndicate of the University of Cambridge, 2004.
  • 8
    National Institute for Clinical Excellence. Guide to the methods of technology appraisal. London: NHS, 2004.
  • 9
    Percudani M, Barbui C, Tansella M. Effect of second-generation antipsychotics on employment and productivity in individuals with schizophrenia: an economic perspective. Pharmacoeconomics 2004;22:70118.
  • 10
    Salkever D, Slade E, Karakus M. Differential effects of atypical versus typical antipsychotic medication on earnings of schizophrenia patients: estimates from a prospective naturalistic study. Pharmacoeconomics 2006;24:12339.
  • 11
    Heeg BMS, Buskens E, Knapp M, et al. Modelling the treated course of schizophrenia: development of a discrete event simulation model. Pharmacoeconomics 2005;23:1733.
  • 12
    Laux G, Heeg BMS, Van Hout BA, Mehnert A. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. Pharmacoeconomics 2005;23:4961.
  • 13
    Chue PS, Heeg BMS, Buskens E, Van Hout BA. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. Pharmacoeconomics 2005;23:6274.
  • 14
    Lieberman J, Stroup S, McEvoy P, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:120923.
  • 15
    Adelphi Group. Psychoses DSP: UK Wave IX [presentation] Janssen Pharmaceutica, UK. 2005.
  • 16
    NICE. Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. London: NHS, 2002.
  • 17
    Travis MJ, Peters E, Kerwin R. Managing Relapse in Schizophrenia. London: Science Press, 2001.
  • 18
    Carlson CD, Cavazzoni PA, Berg PH et al. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. J Clin Psychiatry 2003;64:898906.
  • 19
    Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004;161:41425.
  • 20
    Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry 2004;6(Suppl. 2):37.
  • 21
    Nasrallah HA. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003;28:8396.
  • 22
    Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperisone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002;325:243.
  • 23
    Soares BG, Fenton M, Chue P. Sulpiride for schizophrenia. Cochrane Database Syst Rev 2000;2: CD001162.
  • 24
    Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361:15819.
  • 25
    Coutinho E, Fenton M, Quraishi S. Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses. Cochrane Database Syst Rev 2000;2:CD001164.
  • 26
    Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:1622.
  • 27
    El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev 2006;2:CD004578.
  • 28
    Mota NE, Lima MS, Soares BG. Amisulpride for schizophrenia. Cochrane Database Syst Rev 2002;2:CD001357.
  • 29
    Jayaram MB, Hosalli P. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst Rev 2005;2:CD005237.
  • 30
    Bagnall A, Lewis RA, Leitner ML. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database Syst Rev 2000;4:CD001945.
  • 31
    Johnson & Johnson Pharmaceutical Research & Development LLC. Extended Release OROS Paliperidone in the Treatment of Schizophrenia. Module 2.5—Clinical Overview. R076477. 2006.
  • 32
    Srisurapanont M, Maneeton B, Maneeton N. Quetiapine for schizophrenia. Cochrane Database Syst Rev 2004;2:CD000967.
  • 33
    Tuunainen A, Wahlbeck K, Gilbody SM. Newer atypical antipsychotic medication versus clozapine for schizophrenia. Cochrane Database Syst Rev 2000;2:CD000966.
  • 34
    Wahlbeck K, Cheine M, Essali MA. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2000;2:CD000059.
  • 35
    Lenert L, Sturley A, Rapaport M, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res 2004;71:15565.
  • 36
    Heeg B, Cahn W, Meijboom M, et al. Relation between symptoms in schizophrenia and risk of harm to self and others. ISPOR 8th Annual European Congress 2005. Florence.
  • 37
    The Information Centre. Hospital episode statistics— 2005-06. 2006.
  • 38
    Weiden P, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:88691.
  • 39
    Schooler N, Rabinowitz J, Davidson M, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005; 162:17.
  • 40
    Hunt GE, Bergen J, Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr Res 2002;54:25364.
  • 41
    Hogarty GE. Depot neuroleptics: the relevance of psychosocial factors—a United States perspective. J Clin Psychiatry 1984;45:3642.
  • 42
    Tollefson GD, Beasly CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 2002;154:45765.
  • 43
    Robinson D, Woerner M, McMeniman M, et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 2004;161:4739.
  • 44
    Leucht S, Barnes T, Kissling W, et al. Relapse prevention in schizophrenia with new generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003;160:120922.
  • 45
    Kay S. Positive and Negative Syndromes in Schizophrenia. New York: Brunner/Mazel, Inc., 1991.
  • 46
    Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:13716.
  • 47
    Emsley RA, Raniwalla J, Bailey PJ, Jones AM. A comparison of the effects of quetiapine (‘seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol 2000;15:12131.
  • 48
    Revicki D, Genduso L, Hamilton S, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Quality Life Res 1999;8:41721.
  • 49
    Lindenmayer JP, Czobor P, Volavka J, Lieberman JA. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. J Clin Psychiatry 2004;4:5516.
  • 50
    Rubio G, Martinez I, Ponce G, et al. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry 2006;51:5319.
  • 51
    Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:55364.
  • 52
    Thieda P, Beard S, Richter A, Kane J. An economic review of compliance therapy with medication in the treatment of schizophrenia. Psychiatr Serv 2003;54:50816.
  • 53
    Olfson M, Mechanic D, Hansell S, et al. Predicting medication non-compliance after hospitalization dis charge among patients with schizophrenia. Psychiatr Serv 2000;51:21622.
  • 54
    Fleischhacker W, Oehl M, Hummer M. Factors influencing compliance in schizophrenia patients. J Clin Psychiatry 2003;64:S3S9.
  • 55
    Remington G, Adams M. Depot neuroleptic therapy: clinical considerations. Can J Psychiatry 1995;40:S5S11.
  • 56
    Gerlach J. Depot neuroleptics in relapse prevention: advantages and disadvantages. Int Clin Psychopharmacol 1995;9:S1720.
  • 57
    Dolder C, Lacro J, Dunn L, Jeste D. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002; 159:1038.
  • 58
    Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:6929.
  • 59
    Zhou H, Isaman DJM, Messinger S, et al. A computer simulation model of diabetes progression, quality of life, and cost. Diabetes Care 2005;28:285663.
  • 60
    Landy J, Stein J, Brown MM, et al. Patient, community and clinician perceptions of the quality of life associated with diabetes mellitus. Med Sci Monit 2002;8:CR5438.
  • 61
    Siddique R, Markowitz J, Engelhart L. Impact of Atypical Antipsychotic Drug Sedation on Quality of Life. Atlanta, GA: American Psychiatric Association, 2005.
  • 62
    British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. London: NHS, 2005.
  • 63
    Curtis L, Netten A. Unit Costs of Health and Social Care. Kent: Personal Social Services Research Unit, 2004.
  • 64
    Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000;17:479500.
  • 65
    Van Hout BA, Al MJ, Gordon GS, Rutten FF. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994;3:30919.
  • 66
    Helbling J, Ajdacic-Gross V, Lauber C, et al. Attitudes to antipsychotic drugs and their side effects: a comparison between general practitioners and the general population. BMC Psychiatry 2006;6:42.
  • 67
    Rettenbacher MA, Hofer A, Eder U, et al. Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication. J Clin Psychiatry 2004;65:121118.
  • 68
    Turner MS, Stewart DW. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses. J Psychopharmacol 2006;20(6 Suppl.):2037.
  • 69
    Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia. Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:107987.
  • 70
    Mahmoud R, Engelhart L, Janagap C, et al. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder; symptoms, quality of life and resource use under customary clinical care. Clin Drug Invest 2004;24:27586.
  • 71
    Kane JM, Meltzer HY, Carson WH Jr, et al. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry 2007; 68:21323.
  • 72
    Rabinowitz J, Lichtenberg P, Kaplan Z, et al. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001;158:2669.
  • 73
    Tunis S, Faries D, Nyhuis AW, et al. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health 2006;9:7789.
  • 74
    Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003;290:2693702.
  • 75
    Lewis SW, Davies L, Jones PB, et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess 2006;10:iiixi, 1.
  • 76
    Lieberman JA. Comparative effectiveness of antipsychotic drugs. A commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Arch Gen Psychiatry 2006;63:106972.
  • 77
    Mason P, Harrison G, Glazebrook C, et al. The course of schizophrenia over 13 years. A report from the International Study on Schizophrenia (ISos) coordinated by the World Health Organisation. Br J Psychiatry 1996;169:5806.
  • 78
    Lenoir M, Dingemans P, Linszen DH, et al. Social functioning and the course of early onset schizophrenia: five-year follow-up of a psychosocial intervention. Br J Psychiatry 2001;179:538.
  • 79
    Knapp M. Cost of schizophrenia. Br J Psychiatry 1997;171:50918.
  • 80
    Guest J, Cookson R. Cost of schizophrenia to UK society: an incident based cost-of-illness model for the first 5 years following diagnosis. Pharmacoeconomics 1999;15:597610.
  • 81
    Ascher-Svanum H, Zhu B, Faries D, et al. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 2006;6:8.
  • 82
    Tiihonen J, Walhbeck K, Lonnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006; 333:224.
  • 83
    Carpenter W, Buchanan R. Schizophrenia. N Engl J Med 1994;330:68190.
  • 84
    Netten A, Curtis L. Unit Costs of Health Care and Social Care. Canterbury: PSSRU, 2002.